Cart
sales@molnova.com
Isopropyl 2-ethylhexanoate
CAS No. 67024-46-8
Isopropyl 2-ethylhexanoate( —— )
Catalog No. M37423 CAS No. 67024-46-8
Isopropyl 2-ethylhexanoate (Propan-2-yl 2-ethylhexanoate) participates in the synthesis of ink thickeners.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 30 | In Stock |
|
| 25MG | 44 | In Stock |
|
| 50MG | 62 | In Stock |
|
| 100MG | 86 | In Stock |
|
| 200MG | 124 | In Stock |
|
| 500MG | 206 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIsopropyl 2-ethylhexanoate
-
NoteResearch use only, not for human use.
-
Brief DescriptionIsopropyl 2-ethylhexanoate (Propan-2-yl 2-ethylhexanoate) participates in the synthesis of ink thickeners.
-
DescriptionIsopropyl 2-ethylhexanoate (Propan-2-yl 2-ethylhexanoate) participates in the synthesis of ink thickeners.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number67024-46-8
-
Formula Weight186.29
-
Molecular FormulaC11H22O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCCCC(CC)C(=O)OC(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
2, 7-Dihydroxy-4, 6-...
3,5-Dimethoxy-2,7-phenanthrenediol (compound 2) is a phenanthrene compound isolated from the roots of Combretum laxum. 3,5-Dimethoxy-2,7-phenanthrenediol is cytotoxic to human cancer cell lines 786-0, MCF-7 and NCI/ADR-RES, with IC50s of 73.26 μM, 118.40 μM and 83.99 μM respectively. 3,5-Dimethoxy-2,7-phenanthrenediol also has free radical scavenging activity with an IC50 of 20.4 μM.
-
Z433927330
Z433927330 is a potent and selective Aquaporin-7 (AQP7) inhibitor(IC50s of 0.2).Z433927330 inhibits glycerol permeability(IC50 : 0.6 μM).
-
ICCB280
ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient blasts strongly signify that the activity of this compound can overcome resistance to other current therapies for AML with an unfavorable prognosis.
